Cocaine self-administration in rats results in dysfunctional neuroadaptations in the prelimbic (PrL) cortex during early abstinence. Central to these adaptations is decreased phospho-extracellular signal-regulated kinase (p-ERK), which plays a key role in cocaine seeking. Normalizing ERK phosphorylation in the PrL cortex immediately after cocaine self-administration decreases subsequent cocaine seeking. The disturbance in ERK phosphorylation is accompanied by decreased phosphorylation of striatal-enriched protein tyrosine phosphatase (STEP), indicating increased STEP activity. STEP is a well-recognized ERK phosphatase but whether STEP activation during early abstinence mediates the decrease in p-ERK and is involved in relapse is unknown. Here, we show that a single intra-PrL cortical microinfusion of the selective STEP inhibitor, TC-2153, immediately after self-administration suppressed post-abstinence contextinduced relapse under extinction conditions and cue-induced reinstatement, but not cocaine prime-induced drug seeking or sucrose seeking. Moreover, an intra-PrL cortical TC-2153 microinfusion immediately after self-administration prevented the cocaine-induced decrease in p-ERK within the PrL cortex during early abstinence. Interestingly, a systemic TC-2153 injection at the same timepoint failed to suppress post-abstinence context-induced relapse or cueinduced reinstatement, but did suppress cocaine prime-induced reinstatement. These data indicate that the STEPinduced ERK dephosphorylation in the PrL cortex during early abstinence is a critical neuroadaptation that promotes relapse to cocaine seeking and that systemic versus intra-PrL cortical inhibition of STEP during early abstinence differentially suppresses cocaine seeking.
INTRODUCTION
Cocaine self-administration (SA) causes a transient dephosphorylation of critical neuronal plasticity-related proteins in the prelimbic (PrL) cortex of rats that leads to subsequent relapse to cocaine seeking. The phosphoproteins affected by cocaine include extracellular signalregulated kinase (ERK), cyclic adenosine monophosphate response element-binding protein and the N-methyl-D-aspartate (NMDA) receptor subunits GluN2A Y1325 and Glun2B Y1472 (Whitfield et al. 2011; Go, Barry, & McGinty 2016) . A single intra-PrL cortical microinfusion of brainderived neurotrophic factor (BDNF) immediately following the final SA session normalizes all phosphoproteins, prevents cocaine SA-depressed basal levels of glutamate within the nucleus accumbens core and suppresses relapse to cocaine seeking for weeks after the infusion (Berglind et al. 2007 (Berglind et al. , 2009 Whitfield et al. 2011; Go et al. 2016) . Further, infusing a mitogen-activated protein kinase inhibitor (U0126) into the PrL cortex prior to BDNF prevents BDNF's ability both to normalize ERK phosphorylation during early abstinence and to suppress subsequent cocaine seeking (Whitfield et al. 2011) . Collectively, these findings indicate that early abstinence from cocaine SA is a critical timepoint when transient hypoactivity of ERK signaling in the PrL cortex promotes dysfunctional corticostriatal glutamatergic neurotransmission, facilitating relapse to cocaine seeking. A major question is how cocaine SA causes ERK dephosphorylation in the PrL cortex. Of several phosphatases that dephosphorylate ERK, the striatal-enriched protein tyrosine phosphatase (STEP) has emerged as a fundamental regulator of the ERK cascade in response to dopamine and glutamate interactions in the striatum triggered by psychostimulants (Valjent et al. 2005) . STEP is a central nervous system-specific tyrosine phosphatase localized to dopaminoceptive neurons with high expression in the striatum (Lombroso et al. 1993) and moderate expression in the medial prefrontal cortex (PFC) (Boulanger et al. 1995) . Canonically, STEP is activated by Ca 2+ influx through GluN2B-containing NMDA receptors (Paul et al. 2003) , leading to a calcineurin-dependent phosphatase cascade that culminates in the dephosphorylation and activation of STEP (Paul et al. 2003; Valjent et al. 2005; Goebel-Goody et al. 2012) . Following activation, STEP dephosphorylates regulatory tyrosine residues on various substrates implicated in neuronal plasticity, including ERK (Paul et al. 2003; Paul & Connor 2010) , the Src family kinase, Fyn (Nguyen, Liu, & Lombroso 2002) , GluN2A (Tian et al. 2016) and GluN2B (Braithwaite et al. 2006) .
Striatal-enriched protein tyrosine phosphatase activity is augmented in several neuropsychiatric and neurodegenerative disorders. For example, STEP activity is elevated in human post-mortem samples and in animal models of Alzheimer's disease (Snyder et al. 2005; Kurup et al. 2010 ), Parkinson's disease and schizophrenia (Xu et al. 2016b) . Moreover, inhibition of STEP with systemic injections of the novel, relatively selective inhibitor, TC-2153, significantly improves memory deficits in a mouse model of Alzheimer's disease (Xu et al. 2014) as well as phencyclidine-induced hyperlocomotion in mice (Xu et al. 2016a) . TC-2153 treatment reverses the biochemical, electrophysiological and cognitive deficits in mouse models of schizophrenia and in glutamatergic neurons derived from humaninduced pluripotent stem cells from schizophrenic patients (Xu et al. 2016b) . As expected, TC-2153 acutely increases ERK phosphorylation in vivo (Xu et al. 2016a,b) .
Regarding pre-clinical models of addiction, dephosphorylation events within the PrL cortex during early abstinence from cocaine SA are accompanied by decreased phosphorylation, and thus increased activation, of STEP (Sun, Zelek-Molik, & Mcginty 2013) , suggesting STEP is a likely mediator of the ERK dephosphorylation in the PrL cortex during early abstinence from cocaine SA. Therefore, we investigated whether inhibition of STEP with an intra-PrL cortical microinfusion of TC-2153 immediately following the final SA session would prevent ERK dephosphorylation in the PrL cortex during early abstinence and decrease relapse to cocaine seeking. We also tested whether systemic injections of TC-2153 at the same timepoint would reduce relapse. Our results indicate that intra-PrL administration of TC-2153 immediately following the final SA session suppressed context-induced relapse and cueinduced, but not cocaine prime-induced, reinstatement. Intra-PrL TC-2153 also prevented the cocaine-induced ERK dephosphorylation within the PrL cortex during early abstinence. However, systemic TC-2153 injections at the same timepoint had the opposite effects. Overall, our results indicate that the cocaine-induced activation of STEP is an important regulator of neuroadaptations occurring within the PrL cortex during early abstinence that lead to subsequent cocaine seeking.
MATERIALS AND METHODS

Animal subjects and surgery
Adult male Sprague Dawley rats (n = 166) (Charles Rivers Laboratories, Wilmington, MA, USA) were individually housed on a 12-hour reverse light/dark cycle (lights off at 6 AM). Upon arrival, rats were allowed at least 3 days of acclimation to the vivarium. During this time, they were provided standard rat chow (Harlan, Indianapolis, IN, USA) and water ad libitum. All animal use protocols were approved by the Institutional Animal Care and Use Committee of the Medical University of South Carolina and were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Eighth Edition, 2011). All rats weighed 275-325 g at the time of surgery. On the day of surgery, rats were injected i.p. with a ketamine (66 mg/kg) and xylazine (1.33 mg/kg) mixture for anesthesia and ketorolac (2.0 mg/kg) for analgesia. Rats that underwent SA were implanted in the right jugular vein with chronic indwelling i.v. silastic catheters (Fisher Scientific, Hampton, NH, USA). Catheters were attached by subcutaneous tubing to a backmount that exited from an incision in the back. Following catheterization, rats were either secured in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA) or underwent postoperative recovery care (specified in the suceeding texts). Following securement in the stereotaxic apparatus, 26-gauge bilateral stainless steel guide cannulae (Plastics One, Roanoke, VA, USA) were aimed 1 mm above the PrL cortex (+2.8 mm anteroposterior, +/À0.6 mm mediolateral and À3.0 mm dorsoventral relative to bregma). Guide cannulae were fixed to the skull with cranioplastic cement and anchored with steel screws. Following surgery, a bilateral 10-mm stylet was inserted into the guide cannula to prevent blockage, and rats were infused i.v. with 0.1 ml of cefazolin and 0.05 ml of taurolidine-citrate solution (Access Technologies, Skokie, IL, USA). Post-operative care was conducted for 5 days, during which rats were inspected for abnormalities, and catheters were flushed with 0.05 ml taurolidine-citrate solution.
Self-administration
Rats were trained to self-administer cocaine on a fixedratio 1 schedule of reinforcement for 12-14 days (2 hours/day; criterion of ≥10 infusions per day), during which rats were food restricted to 20 g of chow to motivate learning. SA was conducted in standard MED-PC operant chambers that contained two retractable levers (Fairfax, VT, USA) and were housed within soundattenuating cubicles fitted with a fan for airflow and masking noise. Active lever presses elicited a light and tone cue complex followed by a 0.2 mg/50 μl infusion of cocaine hydrochloride (NIDA, Research Triangle Park, NC, USA), followed by a 20-second timeout period. Yoked-saline controls received a non-contingent infusion of 0.9 percent saline (with light and tone cues) when their cocaine partner received a contingent cocaine infusion. For all experiments, inactive lever presses had no programmed consequence. Sucrose SA was conducted in the same manner as cocaine SA experiments, except active lever presses were reinforced with a single 45-mg chocolate-flavored sucrose pellet (BioServe-F07256, Flemington, NJ, USA).
Intracranial microinfusions
Prior to intracranial microinfusions, rats were habituated to a different behavioral room equipped with an infusion pump (Harvard Apparatus, MA, USA) containing two gas-tight Hamilton syringes (10 μl) for at least 2 days immediately following their SA sessions. The day prior to their microinfusions, a stylet extending 1 mm past the tip of the guide cannula was inserted. Immediately following their final SA session, rats were infused (0.5 μl/ hemisphere and 0.25 μl/minute) with either vehicle (0.01 percent dimethyl sulfoxide in filtered 0.1 M phosphate-buffered saline) or 1 μM of TC-2153. Injectors (33 gauge) were left in place for 1 minute after infusions to facilitate diffusion. Following microinfusions, rats were either returned to the vivarium for 6 days of homecage abstinence or were rapidly decapitated 2 hours later for phospho-protein analysis.
Systemic injections
TC-2153 (2.0 mg/ml) was dissolved in 18 percent dimethyl sulfoxide/2 percent Tween 20 in filtered 0.1 M phosphate-buffered saline, and rats were injected (i.p.) with a volume 2.5× their body weight to achieve a final dose of 5 mg/kg, immediately after the final SA session. Six and 10 mg/kg have been shown to increase phospho-ERK (p-ERK) in mice in vivo (Xu et al. 2014 (Xu et al. , 2016a . However, due to solubility restrictions (4 mg/ ml did not stay in solution in our hands), we tested only 5 mg/kg. Following injections, rats were returned to the vivarium for 6 days of homecage abstinence.
Post-abstinence relapse test, extinction, cue-induced and cocaine prime-induced reinstatement
Following abstinence, rats underwent a post-abstinence (PA) relapse test under extinction conditions (active lever presses had no programmed consequence). After at least 6 days (no more than 21 days) of further extinction training to a criterion of an average of ≤15 presses on the active lever over the last 3 days, rats underwent a 2-hour cue-induced reinstatement test. During this test, active lever presses elicited the cocaine-associated cue complex, but no infusion. Following further extinction, rats underwent a 2-hour cocaine prime-induced reinstatement test (10 mg/kg, i.p.) under extinction conditions. Following the cocaine prime test, rats were decapitated with anesthesia to confirm accuracy of cannula placements.
Histology
Following decapitation, brains were extracted, rapidly frozen in isopentane and stored at À80°C. Brains were either coronally sectioned (40 μM) with a cryostat and Nissl-stained to confirm cannula placements, or a single 3-mm-wide × 2-mm-deep tissue punch through the dorsomedial PFC (AP +~4.68-2.76) was taken using a modified biopsy punch (Braintree Scientific, Braintree, MA, USA) and stored at À80°C until processing. Cannula placements were confirmed during dissection (Fig. 1a) .
Tissue processing
Tissue processing was performed as previously described (Sun et al. 2013) . Briefly, 115 μl of ice-cold radioimmunoprecipitation assay buffer (in mM: 50 Tris-HCL, pH 7.4, 150 NaCl, 2 ethylenediaminetetraacetic acid, pH 7.4 and 10 percent glycerol, 1 percent Triton X, 1 percent NP-40 and 1 percent sodium deoxycholate) with a complete set of protease and phosphatase inhibitors, was added to each punch. Punches were briefly sonicated, incubated in ice-cold buffer for 30 minutes and centrifuged at 10 000 × g for 20 minutes at 4°C, and the supernatant was used for all analyses. Protein concentrations were determined using a standard bicinchoninic acid assay. Lysates were then diluted to 2 μg/μl in 0.1× Sample Buffer (Protein Simple, San Jose, CA, USA) and individually aliquoted.
The Wes ™ capillary electrophoresis system (Protein Simple, Bio-Techne, San Jose, CA, USA) was used for protein quantification. Aliquots of lysates (2 μg/μl) were thawed and further diluted in 0.1× Sample Buffer to 0.8 μg/μl for analysis of p-ERK and 0.4 μg/μl for analysis of total ERK (t-ERK) using a combination of ¾ 0.1× Sample Buffer and ¼ 4× Master Mix (1:1 mix of 40 mM dithiothreitol and 10× Sample Buffer, Protein Simple, San Jose, CA, USA) according to the manufacturer's instructions. Samples were denatured at 95°C for 5 minutes. A rabbit primary antibody against p-ERK1/2 (1:50, Cell Signaling Technology-9101S RRID:AB_331646) was multiplexed with a primary antibody against calnexin (Enzo Life Sciences-ADI-SPA-860-F RRID:AB_11178981) at a concentration of 1:2000. A rabbit primary antibody against t-ERK1/2 (1:100, Cell Signaling Technology-9102S RRID: AB_10695746) was multiplexed with 1:1000 calnexin. Supplier anti-rabbit secondary antibodies were used as instructed (Protein Simple, San Jose, CA, USA). Each plate contained samples from all experimental groups, and both p-ERK2 and t-ERK2 were analyzed for each sample from the same aliquot. Analysis of electropherogram peaks was performed using Compass ™ software (Protein Simple) using the Gaussian distribution of the area under the curve of the peak luminolperoxidase signal in the capillaries. Analysis was performed by dividing the area under the curve of p-ERK2 by t-ERK2. Data are expressed as a fold change relative to the respective controls. Figure 1b shows the timeline for all experimental procedures conducted. Experiment 1 was conducted to determine the optimum concentration of TC-2153 that increased p-ERK when microinfused into the PrL cortex. Rats received a single intra-PrL cortical microinfusion of vehicle or TC-2153 (0.5, 1 or 5 μM) and were rapidly decapitated 2 hours later. These concentrations were chosen based on previous work showing that treatment of cortical cultures with concentrations of TC-2153 ranging from 1 to 5 μM increased p-ERK (Xu et al. 2014) . The timepoint was chosen because the cocaine-induced dephosphorylation of ERK in the PrL cortex occurring 2 hours after the end of SA is necessary for subsequent cocaine seeking because normalizing ERK dephosphorylation with a single intra-PrL cortical BDNF infusion suppresses cocaine seeking (Whitfield et al. 2011) .
Experimental design
Experiment 2 was designed to determine whether an intra-PrL microinfusion of TC-2153 immediately following the final SA session would suppress relapse after abstinence and extinction. Rats were either microinfused with vehicle or the optimal concentration of TC-2153 (1 μM) from experiment 1 immediately following the final of 12-14 cocaine SA sessions. Following 6 days of forced abstinence, rats underwent a PA context-induced relapse test, further extinction, a cue-induced reinstatement test, further extinction and a cocaine prime-induced Final sample sizes: experiment 1-(0 μM: n = 5, 0.5 μM: n = 7, 1 μM: n = 6 and 5 μM: n = 7); experiment 2-(TC-2153 (1 μM): n = 9, vehicle: n = 13); experiment 3-(saline + vehicle: n = 10, saline + TC-2153: n = 7, cocaine + vehicle: n = 8 and cocaine + TC-2153: n = 9); experiment 4-(TC-2153 (1 μM): n = 7, vehicle: n = 4); and experiment 5-(TC-2153 (5 mg/kg): n = 10, vehicle: n = 11). PA, post-abstinence; SA, self-administration. IC, intra-cranial reinstatement test. In experiment 3, rats either underwent cocaine SA or received yoked-saline infusions and received either an intra-PrL microinfusion of TC-2153 (1 μM) or vehicle immediately after the final SA session. Rats were rapidly decapitated 2 hours later to determine the effect of TC-2153 on the cocaine-induced ERK dephosphorylation within the PrL cortex during early abstinence. Experiment 4 was conducted in the same manner as experiment 2, except active lever presses were reinforced with chocolate sucrose pellets instead of cocaine infusions and there was no sucrose-primed test. The design of experiment 5 was similar to experiment 2, except rats received a systemic injection of TC-2153 (5 mg/kg, i.p.) or vehicle immediately following the final cocaine SA session.
Statistical analysis
All analyses were performed using GRAPHPAD PRISM 7 software (La Jolla, CA, USA). All behavioral data were analyzed with a mixed-model ANOVA with time (SA/extinction versus PA/cue/cocaine prime test) as the within-subject variable and treatment (TC-2153 versus vehicle) as the between-subject variable. If significant main effects or an interaction was observed, Bonferroni-corrected pairwise comparisons were used to compare groups during and across timepoints. Grubbs' test was used to determine statistical outliers, and these were removed from final analyses (n = 4). Data in experiment 1 were analyzed with a one-way ANOVA followed by Dunnett's multiple comparison test to compare all TC-2153 concentrations to the vehicle control group. Data in experiment 3 were analyzed with a two-way ANOVA followed by StudentNeuman-Keuls pairwise comparison tests. All data are expressed as the mean +/À standard error of the mean, and statistically significant differences were determined at P < 0.05.
RESULTS
Experiment 1. Intra-prelimbic microinfusion of TC-2153 increased phospho-extracellular signal-regulated kinase in naïve rats Naïve rats (n = 32; n = 8/group) received a bilateral intra-PrL microinfusion of vehicle or one of three concentrations of TC-2153 (0.5, 1 or 5 μM). Rats were rapidly decapitated 2 hours after the infusion to determine the optimal concentration of TC-2153 that increased p-ERK in the PrL cortex in vivo. Of the 32 rats initially used, two died after surgery, and four brain samples were A one-way ANOVA indicated a significant effect of intra-PrL TC-2153 on p-ERK (F (3,21) = 3.21, P < 0.05). Dunnett's multiple comparison test indicated that only the 1 μM concentration of TC-2153 significantly increased p-ERK relative to vehicle controls (P = 0.04; Fig. 2a & c) . There was no effect of TC-2153 on t-ERK normalized to calnexin (F (3,21) = 0.08, P = 0.97; Fig. 2b  & d) . Thus, for all future microinfusion experiments, we used a 1 μM concentration of TC-2153.
Experiment 2. Intra-PrL microinfusion of TC-2153 suppressed context-induced relapse and cue-induced, but not cocaine prime-induced, reinstatement
We next investigated the effect of a bilateral intra-PrL microinfusion of TC-2153 (1 μM) immediately following SA on context-induced relapse following abstinence, cue-induced and cocaine prime-induced reinstatement following extinction. Two rats died during surgery, 5 rats died before finishing SA, 11 rats were removed from the final analysis because of cannula placements outside of the PrL cortex and 2 rats were outliers according to Grubbs' test during the cue and cocaine prime test in the TC-2153 and vehicle group, respectively. Final group sizes were n = 13 (vehicle) and n = 9 (TC-2153). Infusions earned over the last 3 days of SA did not differ between groups (P = 0.16). After infusions, rats were exposed to 6 days of abstinence followed by a PA test. Results revealed a significant main effect of time (F (1,20) = 6.09, P = 0.02) and treatment (F (1,20) = 8.53, P = 0.009), but no treatment by time interaction (F( 1,20) = 3.30, P = 0.08). Bonferroni-corrected pairwise comparisons indicated that active lever presses were similar between groups during the last 3 days of SA before microinfusions (P > 0.99). Rats infused with vehicle (P < 0.01), but not TC-2153 (P > 0.99), pressed the active lever significantly more during the PA test than during the last 3 days of SA and rats infused with TC-2153 pressed the active lever during the PA test significantly less than vehicle-infused controls (P < 0.01; Fig. 3a) .
After completion of extinction, rats underwent a cueinduced reinstatement test. There was a significant main effect of time (F (1,20) = 88.67, P < 0.0001) and treatment (F (1,20 ) = 8.82, P < 0.01), as well as a significant treatment by time interaction (F (1,20) = 9.80, P < 0.01; Fig. 3b ). Bonferroni-corrected pairwise comparisons indicated that active lever pressing over the last 3 days of extinction did not differ between groups (P > 0.99). Both vehicle-infused (P < 0.0001) and TC-2153-infused (P < 0.01) rats pressed the active lever significantly more during the cue test than during the last 3 days of extinction, and rats infused with TC-2153 pressed the active lever significantly less than vehicle-infused rats (P < 0.001).
Following re-extinction to criterion, rats underwent a cocaine prime-induced reinstatement test (Fig. 3c) . One rat removed its headcap prior to the cocaine prime test and was excluded from the analysis. There was a significant main effect of time (F (1,19) = 54.86, P < 0.0001), indicating that both groups had increased active lever pressing during the cocaine prime-induced reinstatement test relative to the last 3 days of extinction. However, there was no significant main effect of treatment (F (1,19) = 1.857, P = 0.19) or a significant treatment by time interaction (F (1,19) = 0.33, P = 0.57). These results show that a single intra-PrL cortical microinfusion of TC-2153 immediately following SA suppresses cocaine seeking in the PA and cue-induced, but not cocaine prime-induced, reinstatement tests.
Experiment 3. Intra-PrL cortical microinfusion of TC-2153 prevented the cocaine-induced ERK dephosphorylation within the PrL cortex during early abstinence
In order to determine the effect of STEP inhibition on the cocaine-induced ERK dephosphorylation within the PrL cortex during early abstinence, rats (n = 48) were randomly assigned to either cocaine SA or yoked-saline groups following surgery. One rat was removed prior to the end of SA after a catheter failure. Immediately following the final of 12-14 cocaine/yoked saline SA sessions, the PrL cortex of rats was microinfused bilaterally with TC-2153 or vehicle and rapidly decapitated 2 hours after the infusion. Of the remaining 47 rats, 13 were excluded from analyses for the following reasons: cannula placements that were outside of the PrL cortex (n = 6), catheter failure on the final day of SA (n = 1) or tissue samples were punched incorrectly (n = 6). Following exclusion, final group sizes were as follows: saline + vehicle (n = 10), saline + TC-2153 (n = 7), cocaine + vehicle (n = 8) and cocaine + TC-2153 (n = 9). A two-way ANOVA revealed a significant main effect of treatment (TC-2153 versus vehicle) as well as SA (cocaine versus saline) on p-ERK (treatment: F (1,30) = 14.84, P < 0.001 and SA: F (1,30) = 10.28, P < 0.01), but no significant treatment by SA interaction (F (1,30) = 0.08, P = 0.78). Student-Neuman-Keuls tests revealed that p-ERK levels were significantly lower in the cocaine + vehicle group versus the yokedsaline + vehicle group. TC-2153 significantly increased p-ERK in yoked-saline rats (P < 0.05; Fig. 4a & c) and prevented the cocaine SA-induced decrease. There was no effect of treatment, SA or a significant treatment by SA interaction on t-ERK/calnexin (treatment: F (1,30) = 2.28, P = 0.14; SA: F (1,30) = 2.43, P = 0.13; and treatment × SA: F (1,30) = 3.12, P = 0.09; Fig. 4b  & d) . These results indicate that intra-PrL TC-2153 infused immediately following the final SA session prevented the cocaine-induced ERK dephosphorylation within the PrL cortex during early abstinence.
Experiment 4. Intra-PrL cortical microinfusion of TC-2153 did not affect context-induced relapse or cue-induced reinstatement of sucrose seeking
In order to determine whether the suppressive effect of intra-PrL infusion of TC-2153 on relapse was cocainespecific, rats (n = 16) underwent 12-14 days of sucrose SA and were microinfused with either TC-2153 or vehicle immediately following the final SA session. One rat died after surgery, and three rats removed their headcaps prior to the PA test. Of the remaining 12 rats, one was removed from analysis because its cannula Figure 4 A single intra-prelimbic TC-2153 microinfusion prevented the cocaine-induced dephosphorylation of extracellular signal-regulated kinase (ERK) within the prelimbic cortex during early abstinence. (a) Rats microinfused with vehicle immediately following the final cocaine self-administration session show decreased phospho-ERK (p-ERK) relative to yoked-saline rats infused with vehicle. This decrease is prevented in rats that received a TC-2153 microinfusion immediately following cocaine self-administration. Additionally, yoked-saline rats microinfused with TC-2153 showed augmented p-ERK relative to saline-vehicle rats ( * P < 0.05 relative to saline-vehicle and + P < 0.05 relative to cocaine-vehicle). (b) There were no differences between groups in total ERK/calnexin. Representative chemiluminescent peaks for p-ERK (c) and total ERK multiplexed with calnexin (d) for groups in experiment 3. AUC, area under the curve placement was outside of the PrL cortex. Following infusions, rats underwent 6 days of forced abstinence followed by a PA test. A two-way ANOVA revealed a significant main effect of time (F (1,9) = 35.69, P < 0.001; Fig. 5a ), but no main effect of treatment (F (1,9) = 0.00005, P > 0.99) or a significant treatment by time interaction (F (1,9) = 0.01, P = 0.93), indicating that both groups had reduced active lever pressing during the PA test relative to the last 3 days of sucrose SA. Following further extinction to criterion, rats underwent a cue-induced reinstatement test. Results indicated a significant main effect of time (F (1,9) = 37.79, P < 0.001; Fig. 5b ), but not treatment (F (1,9) = 0.31, P = 0.59) or a significant treatment by time interaction (F (1,9) = 1.08, P = 0.33). These data indicate that both groups had increased active lever pressing during the cue-induced reinstatement test relative to the last 3 days of extinction, which was not altered by a prior TC-2153 microinfusion.
Experiment 5. A systemic injection of TC-2153 preferentially suppressed cocaine prime-induced reinstatement
In order to determine the effect of systemic administration of TC-2153 on relapse, rats (n = 28) underwent cocaine SA for 12-14 days as earlier. Three rats became ill and were euthanized prior to the end of SA. Two rats were removed for catheter failure prior to finishing SA. One rat per group was an outlier according to Grubbs' test in the cocaine prime test and was removed from all analyses. The remaining rats were injected i.p. with TC-2153 (5 mg/kg, n = 10) or vehicle (n = 11) immediately following the last of 12-14 cocaine SA sessions. The number of infusions earned over the last 3 days of SA was similar between groups before i.p. injections (P = 0.66). Following 6 days of abstinence, rats were returned to their SA chambers for the PA test. A two-way ANOVA revealed a significant main effect of time (F (1,19) = 23.10, Figure 5 A single intra-prelimbic cortical microinfusion of TC-2153 fails to suppress sucrose seeking after abstinence and extinction. (a) Animals microinfused with TC-2153 or vehicle show equal responding on the active lever during the post-abstinence (PA) test as well as (b) during the cue-induced reinstatement test, but both groups had reduced responding during the PA test relative to the last 3 days of self-administration (SA) and increased responding during the cue test relative to the last 3 days of extinction ( *** P < 0.001 relative to the last 3 days of SA or extinction, two-way ANOVA) Figure 6 Systemic injection of TC-2153 suppressed cocaine prime-induced reinstatement but not post-abstinence (PA) context-induced relapse or cue-induced reinstatement. Rats were either injected with TC-2153 (5 mg/kg, i.p.) or vehicle immediately following the final cocaine selfadministration (SA) session. Both groups had increased active lever pressing during (a) the PA test following 6 days of forced abstinence as well as (b) during the cue-induced reinstatement test following extinction. There was no effect of TC-2153 on active lever pressing in either test. However, TC-2153 injections suppressed (c) cocaine prime-induced reinstatement ( ++++ P < 0.0001, +++ P < 0.001 and + P < 0.05 relative to the last 3 days of SA/extinction and *** P < 0.001 relative to vehicle) P = 0.0001; Fig. 6a ), indicating that both groups had increased active lever pressing in the PA test relative to the last 3 days of SA, but there was no significant main effect of treatment (F (1,19) = 0.18, P = 0.67) or a significant treatment by time interaction (F (1,19) = 0.003, P = 0.96). Following completion of extinction, rats underwent a cue-induced reinstatement test. Results showed a significant main effect of time (F (1,19) = 110.50, P < 0.0001; Fig. 6b ), indicating that both groups pressed the active lever significantly more during the cue-induced reinstatement test compared with the last 3 days of extinction, but there was no main effect of treatment (F (1,19) = 2.50, P = 0.13) or a treatment by time interaction (F( 1,19) = 2.38, P = 0.14).
Following re-extinction to criterion, rats underwent a cocaine prime-induced reinstatement test. There were significant main effects of time (F (1,19) = 42.66, P < 0.0001), treatment (F (1,19) = 7.065, P = 0.02) and a significant treatment by time interaction (F (1,19) = 8.26, P < 0.01; Fig. 6c ). Bonferroni-corrected pairwise comparisons indicated that active lever presses were equal between groups over the last 3 days of extinction (P > 0.99), but rats injected with TC-2153 pressed the active lever significantly less than vehicle-injected rats during the cocaine prime test (P < 0.001). Collectively, these data indicate that injections of TC-2153 immediately following SA preferentially suppress cocaine prime-induced reinstatement.
DISCUSSION
Summary of findings
The results of the current experiments are the first to show that the cocaine-induced activation of STEP in the PrL cortex during early abstinence from cocaine SA (Sun et al. 2013 ) plays a role in relapse. Interestingly, we found that an intra-PrL cortical TC-2153 microinfusion immediately after SA suppressed contextinduced relapse and cue-induced, but not cocaine prime-induced, reinstatement. However, systemic TC-2153 injections had the opposite effect. Additionally, intra-PrL cortical TC-2153 prevented the cocaineinduced ERK dephosphorylation in the PrL cortex during early abstinence. These results corroborate previous findings that early abstinence from cocaine SA is a critical timepoint whereby an intervention, like an infusion of BDNF or TC-2153, that normalizes ERK and/or GluN2 signaling in the PrL cortex produces an enduring suppression of relapse (Whitfield et al. 2011; Go et al. 2016) . This finding coupled with the finding that BDNF does not alter food seeking (Berglind et al. 2007 ) and TC-2153 does not alter sucrose seeking indicates that intra-PrL cortical interventions during early abstinence selectively attenuate cocaine seeking without affecting the motivation to seek natural rewards.
Differential effect of systemic versus intra-prelimbic cortical TC-2153 on cocaine seeking
Recent studies indicate that systemic delivery of TC-2153 normalizes cognitive/behavioral dysfunction in animal models of disorders with augmented STEP activity (Xu et al. 2014; Xu et al. 2016a,b) . However, our experiments are the first to microinfuse TC-2153 and we found that systemic versus intra-PrL cortical TC-2153 differentially suppressed cocaine seeking. Several potential explanations exist for the different effects based on route of administration. The lack of effect of systemic TC-2153 on context-induced relapse and cue-induced reinstatement could be due to the inability of 5 mg/kg TC-2153 to prevent the dephosphorylation of ERK within the PrL cortex during early abstinence from cocaine SA. However, this is unlikely because 5 mg/kg TC-2153 increased p-ERK within the PrL cortex 2 hours after an injection in naïve rats (Supporting Information Fig. S1 ). Alternatively, it is likely that systemic TC-2153 increased p-ERK, as well as other STEP targets, in numerous brain regions outside of the PrL cortex, such as the hippocampus, striatum and amygdala, that countered the elevation of p-ERK in the PrL cortex during context and cueinduced reinstatement and enabled preferential inhibition of cocaine prime-induced reinstatement.
Intra-PrL cortical TC-2153 prevented the cocaine-induced ERK dephosphorylation during early abstinence
The results of the current study are in agreement with previous studies indicating that cocaine SA decreases p-ERK in the PrL cortex during early abstinence (Whitfield et al. 2011; Go et al. 2016) . Consistent with our hypothesis, we show here that this effect was prevented by intraPrL cortical microinfusions of TC-2153. ERK is central to neuroadaptations occurring within neural circuits that mediate drug seeking (Lu et al. 2006; Zhai et al. 2008) . Therefore, it is not surprising that time-course experiments indicate that p-ERK changes dynamically within the PFC during various stages of abstinence from cocaine SA (Whitfield et al. 2011; Miszkiel et al. 2014) . For example, cocaine-mediated decreases in p-ERK in the PrL cortex 2 hours after SA normalize by 22 hours and remain unaltered after 6 days of abstinence (Whitfield et al. 2011) . Importantly, intra-PrL infusion of BDNF is unable to suppress relapse when microinfused after 6 days of forced abstinence (Berglind et al. 2007 ). However, the suppressive effect of BDNF on cocaine seeking when it is microinfused immediately after SA depends on normalizing p-ERK during early abstinence (Whitfield et al. 2011) .
Potential mechanism of striatal-enriched protein tyrosine phosphatase activation during early abstinence Striatal-enriched protein tyrosine phosphatase has been shown to be dephosphorylated and activated by Ca 2+ influx through GluN2B-containing NMDA receptors via a PP2B-PP1-dependent mechanism in corticostriatal cultures (Paul et al. 2003) . Moreover, extrasynaptic NMDA receptor stimulation inactivates ERK in cultured hippocampal and cortical neurons (Kim et al. 2005; Ivanov et al. 2006; Leveille et al. 2008) , whereas synaptic NMDA receptor stimulation leads to STEP ubiquitination, facilitating sustained ERK activation (Hardingham, Arnold, & Bading 2001; Hardingham, Fukunaga, & Bading 2002; Xu et al. 2009 ). Thus, an attractive hypothesis is that a hyperglutamatergic tone arises in the PrL cortex after chronic SA that facilitates extrasynaptic NMDA receptor stimulation, and subsequent activation of STEP, inhibiting NMDA function and associated ERK signaling during early abstinence. In support, not only does cocaine SA lead to the dephosphorylation of ERK and cyclic adenosine monophosphate response element-binding protein but also GluN2A Y1325 and GluN2B Y1472 (Go et al. 2016) , and STEP dephosphorylates GluN2B Y1472 (Braithwaite et al. 2006) . TC-2153 also enhances GluN2A pan-tyrosine phosphorylation in hippocampal cultures. Interestingly, STEP À/À mice have increased GluN2A pan-tyrosine, but not GluN2A Y1325 , phosphorylation (Tian et al. 2016) , suggesting a different tyrosine site in GluN2A may be dephosphorylated by STEP. However, STEP may indirectly dephosphorylate GluN2A Y1325 via dephosphorylation and inactivation of Fyn as demonstrated in vitro (Nguyen et al. 2002) . Thus, future experiments should investigate whether TC-2153 prevents the cocaine-induced GluN2A/B dephosphorylation. Furthermore, an intraPrL cortical microinfusion of Ro-25-6981, a selective GluN2B antagonist, immediately after SA does not reduce relapse (Go et al. 2016) . However, treatment of cortical cultures with memantine, a non-selective NMDA antagonist, preferentially blocks extrasynaptic NMDA receptors (Leveille et al. 2008) , suggesting that preferential inhibition of extrasynaptic GluN2B-containing NMDA receptors may prevent the cocaine-induced activation of STEP, ERK dephosphorylation and subsequent cocaine seeking.
Conclusions
Extracellular signal-regulated kinase dephosphorylation in the PrL cortex during early abstinence represents a critical neuroadaptation that promotes relapse.
Normalizing p-ERK with a single intra-PrL cortical BDNF (Whitfield et al. 2011) or TC-2153 microinfusion immediately after cocaine SA suppresses cocaine seeking. Although BDNF and TC-2153 have a similar effect on cocaine seeking, they are likely producing this effect in different ways. Intra-PrL cortical BDNF immediately after SA is likely acting upstream of STEP by directly increasing activity of mitogen-activated protein kinase signaling during early abstinence (Whitfield et al. 2011) , as well as potentially inducing the degradation of STEP (Saavedra et al. 2015) . However, TC-2153 acts only at the level of STEP to prevent the catalytic activity of STEP following activation (Xu et al. 2014) . Both of these interventions culminate in normalized p-ERK, highlighting the importance of ERK dephosphorylation as a neuroadaptation occurring in the PrL cortex during early abstinence that leads to cocaine seeking. In conclusion, our results reveal an important role of STEP activation in the PrL cortex in regulating cocaine seeking, as well as associated adaptations in p-ERK that occur during early abstinence from cocaine SA.
